AML

Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML

Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML

A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host Disease

ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial

Biomarkers in Bone Marrow Supernatant for Predicting AML Chemosensitivity

The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation

Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML

HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML

Cardioprotection in AML

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

Familial Investigations of Childhood Cancer Predisposition

Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

my.naviGATE: A Guide to After-Treatment Effects for Adolescents and Young Adults

A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation